A synthetic 44-amino acid growth hormone-releasing factor analog FDA approved for reducing excess visceral abdominal adipose tissue in patients with lipodystrophy.
~26 - 38 minutes
Pituitary GHRH Receptor
C221H366N72O67S
Administered via once-daily subcutaneous injection.
Multiple randomized controlled trials published in humans.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for Tesamorelin: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C221H366N72O67S
trans-3-Hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Tesamorelin (trade name Egrifta) incorporates the full 44-amino acid sequence of human GHRH stabilized by a hydrophobic trans-hexenoyl fatty acid moiety at the N-terminus. This structural addition imparts superior enzymatic resistance to DPP-4 cleavage compared to native GHRH (1-44). In randomized trials, Tesamorelin demonstrated significant selective reduction in visceral adipose tissue (VAT) and hepatic steatosis.
Binds with high affinity to pituitary GHRH receptors, stimulating pulsatile synthesis and release of endogenous growth hormone and hepatic IGF-1, which selectively promotes lipolysis in visceral fat depots while preserving subcutaneous adipose.
Peer-reviewed publications, clinical trials, and preclinical research investigating Tesamorelin.
Pivotal phase 3 clinical trial demonstrating that the stabilized GHRH analog tesamorelin selectively reduces pathological visceral abdominal adipose tissue by 15.2% without subcutaneous fat wasting.
Documented literature dosing intervals and published clinical trial protocols.
Frequency: Once daily before bedtime
“Approved standard adult dosage is 2 mg daily administered subcutaneously.”
Frequency: Once daily before bedtime
“Approved standard adult dosage is 2 mg daily administered subcutaneously.”
Biological delivery routes and standardized laboratory reconstitution principles.
Administered via once-daily subcutaneous injection.
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
